Filing Flows › Elite Pharmaceuticals (ELTP) › Q1 FY27 › vs Q1 FY26
Elite Pharmaceuticals (ELTP) Q1 FY27 vs Q1 FY26 (year over year)
Elite Pharmaceuticals's revenue fell $7.9M (-20%) from $40.2M in Q1 FY26 to $32.4M in Q1 FY27. The biggest changes: Abbreviated New Drug Applications Revenue −$7.6M (-19%); Licensing −$212K (-49%). Gross margin 41.7% against 67.7% (-26.0 pts).
Elite Pharmaceuticals, Q1 FY27: revenue $32.4M (-20% year over year), operating margin 23.3%, net earnings $5.9M, operating cash flow $10.1M. The chart draws each line against Q1 FY26, the increases inside each band.
Margins
| Q1 FY27 | Q1 FY26 | Change | |
|---|---|---|---|
| Gross margin | 41.7% | 67.7% | -26.0 pts |
| Operating margin | 23.3% | 54.0% | -30.7 pts |
| Net margin | 18.3% | -14.6% | +32.9 pts |
| Free cash flow margin | 28.6% | 36.2% | -7.6 pts |
Every line
| Line | Q1 FY27 | Q1 FY26 | Change | % |
|---|---|---|---|---|
| Direct Sales to Wholesalers | $16.4M | $19.0M | −$2.6M | -14% |
| Indirect Sales to Wholesalers | $15.7M | $20.7M | −$5.0M | -24% |
| Abbreviated New Drug Applications Revenue | $32.1M | $39.8M | −$7.6M | -19% |
| Licensing | $221K | $433K | −$212K | -49% |
| Revenue | $32.4M | $40.2M | −$7.9M | -20% |
| Gross profit | $13.5M | $27.2M | −$13.7M | -50% |
| Cost of revenue | $18.8M | $13.0M | $5.9M | +45% |
| Other income, net | $187K | −$22.3M | $22.5M | — |
| Operating profit | $7.5M | $21.7M | −$14.2M | -65% |
| Operating expenses | $6.0M | $5.5M | $452K | +8% |
| Pre-tax earnings | $7.7M | −$564K | $8.3M | — |
| Research & development | $2.0M | $1.7M | $358K | +21% |
| General & admin | $3.5M | $3.4M | $145K | +4% |
| Other operating costs | $396K | $447K | −$51K | -11% |
| Net earnings | $5.9M | −$5.9M | $11.8M | — |
| Income tax | $1.8M | $5.3M | −$3.5M | -66% |
| Depreciation | $253K | $275K | −$22K | -8% |
| Share-based compensation | $28K | $52K | −$24K | -46% |
| Working capital & other | $3.9M | $20.3M | −$16.5M | -81% |
| Operating cash flow | $10.1M | $14.8M | −$4.7M | -32% |
| Free cash flow (OCF − capex) | $9.3M | $14.6M | −$5.3M | -36% |
| Capital expenditures | $809K | $218K | $591K | +271% |
Questions
How much did Elite Pharmaceuticals's revenue grow year over year in Q1 FY27?
Elite Pharmaceuticals's revenue fell $7.9M (-20%) from $40.2M in Q1 FY26 to $32.4M in Q1 FY27.
What drove Elite Pharmaceuticals's revenue change in Q1 FY27?
Abbreviated New Drug Applications Revenue −$7.6M (-19%); Licensing −$212K (-49%).